- Anatomy Of The National Drug Code
- Will The FDA Delay The DSCSA?
- Just Released - The HDMA EDI ASN Guidance For DSCSA
- Pharma Serialization: Going Totally Global Soon
- DSCSA: Special Privileges For The "Big-3" Wholesale Distributors, Part 1
- The Case Against RFID In Pharma
- DSCSA: Special Privileges For The “Big-3″ Wholesale Distributors, Part 2
Archive for the ‘Supply Network Blog’ Category
I recently read in Pharmaceutical Commerce online magazine about the apparent resolution of the RxUSA lawsuit that had delayed implementaton of a couple of the pedigree provisions of the Federal PDMA (Prescription Drug Marketing Act). While Pharmaceutical Commerce did its usual great job of providing historical context, I thought it might be an appropriate topic for the RxTrace blog. But before I had time to document the history of the PDMA in my own words, Brian Daleiden beat me to it in the Supply Network Blog. So rather than writing my own version, I gladly refer you to his post. Between the Pharmaceutical Commerce article and Brian’s post, I have nothing more to say right now.
The Supply Network Blog is a fairly new publication of TraceLink, the successor to SupplyScape, my former employer. I look forward to hearing more from their blog in the future so I recently subscribed. Check it out and see what you think.
Government and industry between them have made the issues surrounding traceablity and pedigree of medicines confused and fluid – RxTrace is my first choice when I want to untangle the history of these issues and to understand new developments.
RxTrace offers unique context and focus on our industry.
RxTrace is the most informative and most current source for information on tracking pharma using AIDC. Their integration of information on UDI is also rather unique. RxTrace serves the pharma stakeholders as the pharma business model evolves to include services enabled by AIDC.
Been following RxTrace ever since some of the very first postings, and it’s one of my absolutely best sources of serious and thorough analyses, on an otherwise very delicate and complicated topic. Dirk’s writings and articles comes highly recommended, and I’m always looking forward to the next posting. Many thanks from Denmark for sharing your thoughts with us all.
RxTrace is informative and well-written. It’s my ‘go to’ source for information on serialization and DSCSA.
Rx Trace is an excellent source of timely industry insight that take complex topics and makes them easier to digest and understand
Look forward to RxTrace News-helps me to better manage key issues
RxTrace distills the complexities of pharmaceutical supply chain issues to simple concepts and also accurately projects issues on the horizon that industry leaders and legislators should heed.
RxTrace is my go-to source for information surrounding the implementation and implications of the Drug Quality and Security Act.
I rely heavily on RxTrace to understand what is changing with the DSCSA, the latest with the FDA and the industry in general.
Counterfeiting as a Form of Free Advertising - Harvard Business Review lnkd.in/bs9Bptv
FDA Announces Major Agency Reorganization, With Focus on Drug Quality | RAPS lnkd.in/b24wN28
October 18, 2014 (4:37)
Will GS1's EPCIS Be Used Widely For DSCSA Data Exchange?Thanks Dirk, great outlook. My humble vision is that EPCIS is gaining moment...
September 23, 2014 (6:19)
Is Your Drug Exempt From The Federal Drug Supply Chain Security Act? RevisitedThanks, Dirk. Take it from someone who has lived and (almost) died with Flor...
Dirk A. Rodgers
September 23, 2014 (2:34)
Is Your Drug Exempt From The Federal Drug Supply Chain Security Act? RevisitedRobert, Thanks. I agree that the DSCSA clearly only applies to finished dosa...
September 23, 2014 (12:45)
Is Your Drug Exempt From The Federal Drug Supply Chain Security Act? RevisitedDirk, Your essays decoding the DSCSA are spot-on, a real pleasure to read....
Dirk A. Rodgers
September 22, 2014 (2:48)
Is Your Drug Exempt From The Federal Drug Supply Chain Security Act?Larry, Sorry for the long delay in replying. Your question requires some res...